Skip to content Skip to sidebar Skip to footer

Newsletter

Life Sciences

Here are Our 11 Top ASX Stocks to Buy in FY26: 1 From Each Sector!

It is a New Financial Year, so it's time to outline 11 Top ASX Stocks to Buy in FY26. Why 11 you might ask? Because 11 is the number of 'GICS' (Global Industry Classification Sectors) on the ASX, and we're picking one from each sector. Our 11 Top ASX Stocks to Buy in FY26! Energy: Ampol…

ByNick SundichJuly 7, 2025

When investors are in a risk off mindset: Here are the 5 moves they usually make and why

Israel’s strikes on Iran, and the subsequent responses, led to the typical "risk off" moves professional investors usually make when faced with uncertainty. But what exactly does "risk off" mean and how relevant is it for retail investors? Should you be risk off too or should you ride out geopolitical uncertainty? Few would've predicted Israel would've…

ByNick SundichJune 18, 2025

How to stop the ASX decline? ASIC and investors have some radical ideas

Addressing the ASX decline is a question that has been considered for many months now. In 2023-24, more companies left the ASX in the past 2 years than any 2 year period since the 1990s recession - whether being brought out by private equity or a big industry player, delisting to a penny stock exchange…

ByNick SundichJune 6, 2025

Will Ozempic hurt healthcare stocks? Here are 5 reasons we don’t think so

Will Ozempic hurt healthcare stocks? Investors who've been selling healthcare stocks left right and centre - except Novo Nordisk of course, now the largest stock in Europe by market capitalisation - believe it will. But even though we hear these arguments loud and clear, we think these fears are overblown. Ozempic is a weight-loss drug that…

ByNick SundichMay 28, 2025

ESG Investing in 2025: How can I tell if a stock or fund is ethical or ESG compliant?

ESG investing is becoming increasingly popular with investors. But as this happens, it begs the question as to just how you can tell if an applicable stock or fund is ESG friendly? So how can I tell if my stock or fund is ESG compliant? As tough as it is to disappoint our readers, there is no…

ByNick SundichMay 26, 2025

This Time is Different: John Templeton said this phrase was costly in 1933, but here is when it may be true

'The investor who says, "This time is different," when in fact it’s virtually a repeat of an earlier situation, has uttered among the four most costly words in the annals of investing'. This quote was said by John Templeton’s in his work '16 rules for Investment Success'. Why Templeton thought 'This Time is Different' was…

ByNick SundichMay 21, 2025

Warren Buffett is retiring, will hand the top job at Berkshire to Greg Abel by the end of 2025. Here’s what you need to know

After many decades at the helm of Berkshire Hathaway, Warren Buffett is retiring. After founding his empire in 1965, he built it into a US$1tn+ empire owning many of America's best companies and profiting off them. But of course, all good things must come to an end - at least a tenure led by the…

ByNick SundichMay 5, 2025

The equity markets in 2025 may rebound hard, according to this scenario

There's hope for equity markets in 2025 When the market is crashing as hard as it has been doing in the last few trading sessions, not many investors want to look too far out or think about upside scenarios in the medium term. And that is probably the case this time around as well with…

ByMarc KennisApril 8, 2025

Should you use your tax cut to invest in stocks? And how should you go about it?

Should you use your tax cut to invest in stocks? With another unexpected round of tax cuts starting from the middle of next year, unveiled in the federal budget earlier this week, this is a question facing many. This round isn't that large - only $536 a year and little over $10 a week by…

ByNick SundichMarch 27, 2025

Recce’s R327G passed its Phase 2 trial with a 93% primary efficiacy endpoint!

Recce Pharmaceuticals (ASX:RCE) has completed its Phase 2 ABSSSI Clinical Trial (Acute Bacterial Skin and Skin Structure Infections) for RECCE® 327 Topical Gel (R327G) and released the results earlier this week. The results were positive, and pave the way for commercialisation as early as 2026. How Recce got to this point Recce is a biotech company focused…

ByNick SundichFebruary 19, 2025

the Kick-ass Multipurpose WordPress Theme

Life Sciences

Here are Our 11 Top ASX Stocks to Buy in FY26: 1 From Each Sector!

When investors are in a risk off mindset: Here are the 5 moves they usually make and why

How to stop the ASX decline? ASIC and investors have some radical ideas

Will Ozempic hurt healthcare stocks? Here are 5 reasons we don’t think so

ESG Investing in 2025: How can I tell if a stock or fund is ethical or ESG compliant?

This Time is Different: John Templeton said this phrase was costly in 1933, but here is when it may be true

Warren Buffett is retiring, will hand the top job at Berkshire to Greg Abel by the end of 2025. Here’s what you need to know

The equity markets in 2025 may rebound hard, according to this scenario

Should you use your tax cut to invest in stocks? And how should you go about it?

Recce’s R327G passed its Phase 2 trial with a 93% primary efficiacy endpoint!

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Life Sciences

Stocks in Spotlight

Add Your Heading Text Here